ASP Isotopes Target of Unusually High Options Trading (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI) was the recipient of unusually large options trading on Friday. Stock investors purchased 24,375 call options on the company. This is an increase of 32% compared to the typical volume of 18,511 call options.

Analysts Set New Price Targets

Several analysts have recently weighed in on ASPI shares. Cantor Fitzgerald started coverage on shares of ASP Isotopes in a research note on Thursday, December 4th. They set an “overweight” rating and a $13.00 price target for the company. Loop Capital set a $15.00 price objective on ASP Isotopes in a report on Monday, October 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a research report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $13.00.

Insider Buying and Selling

In related news, CFO Heather Kiessling sold 80,000 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total transaction of $464,000.00. Following the completion of the transaction, the chief financial officer owned 732,500 shares in the company, valued at $4,248,500. The trade was a 9.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert Ainscow sold 8,438 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $6.20, for a total value of $52,315.60. Following the completion of the sale, the chief executive officer owned 1,546,255 shares in the company, valued at approximately $9,586,781. The trade was a 0.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 528,091 shares of company stock valued at $3,539,245. Insiders own 14.40% of the company’s stock.

Institutional Trading of ASP Isotopes

Several institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in shares of ASP Isotopes in the third quarter valued at approximately $34,000. Ameritas Investment Partners Inc. boosted its stake in ASP Isotopes by 41.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after buying an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the last quarter. Close Asset Management Ltd purchased a new stake in ASP Isotopes in the 3rd quarter valued at $72,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of ASP Isotopes by 96.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares during the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Trading Up 16.6%

ASPI opened at $7.51 on Friday. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04. The firm has a market cap of $832.41 million, a price-to-earnings ratio of -5.78 and a beta of 3.47. The stock has a fifty day moving average price of $6.62 and a 200-day moving average price of $8.40. ASP Isotopes has a 12 month low of $3.65 and a 12 month high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last announced its earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. As a group, equities research analysts anticipate that ASP Isotopes will post -0.24 earnings per share for the current fiscal year.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.